BIOPTIMUS
20.2.2024 09:01:26 CET | Business Wire | Press release
Today, French startup Bioptimus emerged from stealth following a seed funding round of $35M. Under the leadership of Professor Jean-Philippe Vert, PhD, Bioptimus unites a world-class team of scientists from Owkin and Google DeepMind alumni to transform biology with cutting-edge AI foundation model technologies that capture the various scales of biology. This funding round is led by Sofinnova Partners, with Bpifrance Large Venture, and additional support from global funds based in France, including Frst and multistage VC Cathay Innovation. Top global tech investors Headline, Hummingbird, NJF Capital, Owkin and Top Harvest Capital, as well as notable tech entrepreneur Xavier Niel, have joined the round to create a global leader in AI for biology in France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220205004/en/
Professor Jean-Philippe Vert, PhD, co-founder and CEO of Bioptimus, Chief R&D Officer of Owkin and former Research Lead at Google Brain, said: “The application of foundation models and generative AI to biology is set to have a profound impact in science. By harnessing the power of foundation models and advanced algorithms trained on massive amounts of biological and multimodal data across scales, we aim to capture the laws of biology that have hitherto remained too complex to be properly understood. This holistic understanding of biology across scales will be critical to accelerate biomedical and environmental science.”
Edward Kliphuis, Partner at Sofinnova Partners, added: “Foundation models in biology are game-changers. They unlock unprecedented potential to personalize medicine, capturing the uniqueness of each individual while harnessing the collective knowledge of all. Bioptimus stands out by seamlessly blending unparalleled data resources and access, elite talent, and extensive computational power. Together with Sofinnova's deep expertise in life sciences and our expansive network, we're poised to redefine the future of the industry."
Laurent Higueret, Senior Investment Director at Bpifrance Large Venture, commented: “Founded on the ambition to make a quantum leap in our understanding of the complexity of human biology and bringing together a top team of accomplished experts in the fields of data science and generative AI, Bioptimus holds the promise to go even deeper in the analysis of patients’ data across multiple levels and help unveil biological connections hitherto unthought-of. We at Bpifrance are delighted to team-up with such an impressive team and group of investors and support the development of a category defining company that has the potential to disrupt many R&D activities.”
Bioptimus will benefit from Owkin’s data generation capabilities and federated global access to multimodal patient data sourced from leading academic hospitals worldwide, as well as a best-in-class, scalable and secure computing environment from Amazon Web Services, Inc (AWS). Fueled by an abundance of data from all scales and modalities, this gives the power to create computational representations that establish a strong differentiation against models trained solely on public datasets and a single data modality that are not able to capture the full diversity of biology.
About Bioptimus
Bioptimus is building the first universal AI foundation model in biology to drive advancements in scientific research and biotechnological innovation. Leveraging a team of world-class experts, employing state-of-the-art AI technologies and accessing unique proprietary data at scale, we aim to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond. For more information, please visit https://www.bioptimus.com.
About Owkin
Owkin is a TechBio company that combines the best of human and artificial intelligence to ensure every patient gets the right treatment. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials and develop AI diagnostics. Owkin uses privacy-enhancing federation to access up-to-date multimodal patient data that unlocks AI’s potential to power precision medicine. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation. Owkin founded MOSAIC, the world’s largest multi-omics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and Bpifrance, among others).
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners invests in companies from seed to late-stage, and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop innovations that will positively impact our collective future.
Founded in 1972, Sofinnova Partners has backed over 500 companies and created market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com
About Bpifrance and its Large Venture fund
Bpifrance is the French Public Investment Bank and acts as one-stop-shop offering domestic companies a comprehensive range of financial products and services to support them at every stage of their development including equity, loans, guarantees and export insurances, as well as consultancy or training.
Large Venture - the late-stage VC arm of Bpifrance - is a €1.75 billion fund dedicated to fast-growing, highly innovative startups looking to accelerate organic or external growth. Large Venture was incepted in 2013 with the mission to bring the most promising French technologies from the lab to the market, and ultimately to profitability. Large Venture invests in private and public companies across three main sectors: healthtech and life sciences, digital and greentech. For more information, please visit us at: bpifrance.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220205004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Modon Partners With Montage Hotels & Resorts to Bring Ultra-Luxury Hospitality Brand to Egypt’s Ras El Hekma17.5.2026 13:53:00 CEST | Press release
Montage Ras El Hekma introduces the first branded residences for purchase at the Mediterranean destination, alongside the region’s first Montage resort Abu Dhabi-based Modon Holding and Montage Hotels & Resorts have announced Montage Ras El Hekma, which will introduce the first branded residences for purchase at Ras El Hekma on Egypt’s Mediterranean coast. This is the first Montage resort in Egypt – supporting the emerging city’s growth as a global hub for leisure, business and tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517167234/en/ Modon partners with Montage Hotels & Resorts to bring ultra-luxury hospitality brand to Egypt’s Ras El Hekma (Photo: AETOSWire) Montage Ras El Hekma will feature 200 guestrooms and suites, in addition to 96 Montage Residences, and will offer a curated mix of wellness and leisure amenities, including beachfront swimmable lagoons, a Spa Montage with 13 treatment rooms, and six dini
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center17.5.2026 08:00:00 CEST | Press release
Compact, vault-integrated platform selected through a competitive European tender will bring proton therapy to patients across Southern Italy. Mevion Medical Systems, the global leader in compact proton therapy, today announced that it has been selected to deliver the MEVION S250-FIT Proton Therapy System™ to Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples. The award, made following a competitive European tender, will establish the first proton therapy center in Southern Italy, significantly expanding access to advanced radiation therapy for patients across the region and reducing the need for patients to travel long distances to northern Italy for care. Until now, proton therapy in Italy has only been available at centers located in Northern Italy, requiring patients from Southern Italy to travel significant distances for care. The Pascale project supports a broader strategy to establish Naples as a leading oncology hub and to improve healthcare equity across Italy. “T
TetraMem Announces 22nm Multi-Level RRAM Analog In-Memory Computing SoC Milestone16.5.2026 10:43:00 CEST | Press release
TetraMem Inc., a Silicon Valley–based semiconductor company developing analog in-memory computing (IMC) solutions, today announced the successful tape-out, manufacturing, and initial silicon validation of its MLX200 platform, a 22nm multi-level RRAM-based analog IMC system-on-chip (SoC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260516556464/en/ Photograph of the MLX200 chip with a five-cent coin for size reference The achievement marks a significant step toward the commercialization of analog computing architectures based on emerging non-volatile memory technologies, addressing the growing challenges of data movement, power consumption, and thermal constraints in modern AI systems. As AI workloads continue to scale, system performance is increasingly constrained by the cost of moving data between memory and compute units. Analog in-memory computing offers a fundamentally different approach by performing computation dir
STARTEEPO Invest Announces 5% Stake in Xerox Holdings Corporation15.5.2026 18:15:00 CEST | Press release
STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has acquired a significant ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515594020/en/ As of the date of this release, STARTEEPO and its affiliates beneficially owns 6.6 million shares of Xerox (excluding options), representing approximately 5.05% of the Company’s outstanding common stock. STARTEEPO has filed a Schedule 13D with the U.S. Securities and Exchange Commission (the “SEC”) providing additional details regarding its investment. Investment Perspective STARTEEPO believes that Xerox represents an interesting investment opportunity supported by a combination of balance sheet initiatives, ongoing operational improvements, and its position within a changing and consolidating industry. In STARTEEPO’s view, the Company
NTT DATA Announces Intent to Acquire WinWire to Scale Enterprise AI Adoption and Accelerate Industry Transformation with Microsoft15.5.2026 16:00:00 CEST | Press release
Accelerates AI‑driven transformation through expanded agentic AI and data engineering capabilities that underpin NTT DATA’s AI strategy Adds 1,000 Azure engineers and AI specialists to scale cloud and AI delivery capabilities Advances NTT DATA’s North America leadership position, scaling industry aligned AI led innovation across its cloud services and Microsoft Business Unit Builds on NTT DATA’s position as the fastest-growing Microsoft GSI partner, accelerating co-innovation in enterprise AI NTT DATA, a global leader in AI, digital business and IT services, today announced it has signed a definitive agreement to acquire WinWire,an award-winning Microsoft partner specializing in Agentic AI, AI on Azure, data engineering and cloud-native development as foundational capabilities for enterprise AI. The acquisition strengthens NTT DATA’s position as a trusted partner to help organizations move beyond experimentation to operationalize AI at scale. The acquisition further advances NTT DATA’s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom